Dow Jones
38.225,66 +322,37 (+0,85%) Nasdaq
15.840,96 +235,48 (+1,51%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0738 +0,0010 (+0,10%) Bitcoin EUR
55.447,33 +1.934,35 (+3,61%) CMC Crypto 200
1.282,69 +11,94 (+0,94%)
CytomX Therapeutics, Inc. (CTMX)
Dopo ore:
| Chiusura precedente | 5,1300 |
| Aperto | 4,4000 |
| Denaro | 4,4800 x 100 |
| Lettera | 4,5200 x 100 |
| Min-Max giorno | 4,0700 - 4,7400 |
| Intervallo di 52 settimane | 1,0400 - 5,8500 |
| Volume | |
| Media Volume | 4.331.278 |
| Capitalizzazione | 304,793M |
| Beta (5 anni mensile) | 1,02 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0100 |
| Prossima data utili | 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 2,90 |
GlobeNewswireCytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in September. H.C. Wainwright 25th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Company Presentation: 11:30 a.m. ET Location: New York, NY Cantor Global Healthcare Conference Date: Tuesday, September 26, 2023 Fi
- GlobeNewswire
CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the H.C. Wainwright Immune Cell Engager Virtual Conference on Thursday, August 17 at 9:00 a.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX’s website at www.cytomx.c
- GlobeNewswire
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported second quarter 2023 fin
